Search results
Results From The WOW.Com Content Network
GlaxoSmithKline Pharmaceuticals Ltd is an Indian research-based pharmaceutical and healthcare company, and a subsidiary of GSK. [4] [5] The company's product portfolio includes prescription medicines and vaccines .
GSK plc (an acronym from its former name GlaxoSmithKline plc) is a British multinational pharmaceutical and biotechnology company with global headquarters in London. [3] [4] It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, [n 1] which was itself a merger of a number of pharmaceutical companies around the Smith ...
Novartis. / 47.5744252; 7.5764914. Pharmaceutical drugs, generic drugs, over-the-counter drugs, vaccines, diagnostics, contact lenses, animal health ( list...) Novartis AG is a Swiss multinational pharmaceutical corporation based in Basel, Switzerland. Consistently ranked in the global top five, Novartis is one of the largest pharmaceutical ...
Rotarix (human rotavirus vaccine, live attenuated) Shingrix (for Zoster Vaccine Recombinant, Adjuvanted) Synflorix (pneumococcal polysaccharide conjugate vaccine (adsorbed)) Twinrix (for combined hepatitis A (inactivated virus) and hepatitis B vaccine (genetically derived surface antigen)) Typherix (typhoid vaccine (purified polysaccharide ...
The failure had dealt a blow to GSK's oncology portfolio, but analysts said Thursday's positive results could mean a comeback for the drug. GSK's blood cancer drug meets main goal in late-stage ...
India has the sixth-most sites worldwide. The first sites to be listed were the Ajanta Caves, Ellora Caves, Agra Fort, and Taj Mahal, all of which were inscribed in the 1983 session of the World Heritage Committee. The most recent sites listed were Santiniketan and the Sacred Ensembles of the Hoysalas, in 2023. [3]
(Reuters) - British drugmaker GSK said on Thursday it plans to sell about 385 million shares, representing its entire shareholding, in spun-off consumer healthcare business Haleon.
June 2, 2024 at 8:03 AM. By Pratik Jain. (Reuters) - GSK's multiple myeloma drug Blenrep nearly halved the risk of disease progression or death compared to standard-of-care treatments for the ...